

NJC

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1 **Electron transfer and Fluorescence “turn-off” based CdTe quantum**
2 **dots for vancomycin detection at nanogram level in aqueous serum**
3 **media**

4 **Wanjun Liang^a, Shaopu Liu^a, Zhengqing Liu^b, Dan Li^a, Linlin Wang^a, Chenxia Hao^a**

5 **Youqiu He^{a*}**

6 **Abstract**

7 A simple and sensitive fluorescence “turn-off” biosensor for detection of vancomycin at nanogram
8 level was proposed based on the electron transfer mechanism and the fluorescence quenching of
9 the CdTe quantum dots (QDs). The electron transfer process during the interaction between
10 vancomycin and GSH-CdTe QDs was investigated not only by ultraviolet/visible (UV/vis)
11 absorption and fluorescence (FL) spectroscopy but also by fluorescence lifetime. The degree of the
12 electron transfer and as resulted fluorescence quenching was proportional to the increasing of
13 vancomycin concentrations in of range 1.534 ng mL⁻¹–20 µg mL⁻¹, with a corresponding detection
14 limit of 0.4605 ng mL⁻¹. This proposed a biosensor that could be applied to determine vancomycin
15 in environmental water samples, pharmaceutical formulation and spiked human serum with all of
16 the recoveries over 95.8%. The mechanism about the detection was dynamic quenching with an
17 electron transfer (ET) process. The experimental conditions, key affecting factors and the
18 influence of the coexisting substances have also been optimized and studied.

19 **Keywords:** Vancomycin; Electron transfer; Fluorescence quenching; “ON-OFF” Quantum dots;

^a *Key Laboratory on Luminescence & Real-Time Analysis, Ministry of Education, School of Chemistry and Chemical Engineering, Southwest University, Chongqing 400715, P.R. China. *E-mail address: heyq@swu.edu.cn and lwj518@swu.edu.cn; Tel.: +86 23 68367475; Fax: +86 23 68254000*

^b *Frontier Institute of Chemistry, Frontier Institute of Science and Technology jointly with College of Science, Xi'an Jiaotong University, Xi'an 710054, P.R. China*

20 Introduction


21 The interest in luminescent semiconductor quantum dots (QDs), due to their unique optical
22 and electronic properties, has grown tremendously in both fundamental research and technical
23 applications.¹ Compared with other luminescent materials, QDs have distinct properties such as
24 greater brightness, better stability, higher quantum yield, broad excitation spectrum, narrow and
25 size-tunable emission spectrum.² All of these properties provide them more advantages over
26 traditional organic dyes and lanthanide probes in fluorescent applications. Subtle changes of the
27 QDs result in dramatic changes in their optical properties, which would offer many opportunities
28 for detecting various specific analytes. Therefore, QDs have been increasingly exploited as
29 fluorescent probes and have been widely used in the field of analytical chemistry such as cell
30 labeling, genomic and proteomic detection, DNA analysis, optical sensors etc.³

31 Vancomycin (as shown in Fig. 1) is a glycopeptide antibiotic used in the prophylaxis and
32 treatment of infections caused by Gram-positive bacteria.⁴ Due to early observations of its
33 nephrotoxicity and ototoxicity as well as its intravenous dosing requirements, vancomycin has
34 traditionally been viewed as a drug of "last resort", applied only after treatment with other
35 antibiotics had failed.⁵ However, the emergence of vancomycin-resistant strains which requires
36 higher concentrations in order to be effective has aroused concerns. Monitoring vancomycin in
37 pharmaceutical products is of great importance to prevent side effects in patients under treatment
38 and to achieve optimal therapeutic concentrations.⁶ Moreover, antibiotics including vancomycin
39 have been found in the aquatic environment such as waste and polluted water resources. This
40 compound plays a critical role in the maintenance or extension of antibiotic resistance bacteria,
41 finally resulting in hazards to human health.⁷ Therefore, screening vancomycin both in biological
42 and environmental studies is very important.

43 Many different methods have been used to detect vancomycin in different samples, such as
44 spectrophotometry,⁸ immunoassay,⁹ voltammetry,¹⁰ high performance liquid chromatography
45 (HPLC) with ultraviolet detection,¹¹ capillary electrophoresis (CE),¹² mass spectroscopy
46 detection¹³ and electrochemical detection.¹⁴ However, the above ways for the determination of
47 vancomycin still have some imperfections. The electrochemical detection requires complicated

48 modifications of the electrodes and the HPLC detection needs long time and complex operation.
49 Besides, high cost instrumentation, time consuming procedure and unsuitability for automatic
50 analysis and the need for large amounts of expensive and toxic solvents are some of the reported
51 drawbacks of these methods.¹⁵ These also block the practical application of vancomycin. Thus, it
52 is urgent to develop a sensitive, precise, simple and convenient detection method for vancomycin.

53 It is well known that fluorescence approach has attracted interests due to its high sensitivity
54 and simplicity as useful analytical technique in recent years.¹⁶ Nowadays, with the rapid
55 development of nanotechnology, great attention has been focused on the using of nanoparticles
56 and QDs as the fluorescence probes.¹⁷ Herein, a novel, fast and simple vancomycin measuring
57 method based on the fluorescence of QDs has been unprecedentedly constructed. The interaction
58 between GSH-CdTe QDs and vancomycin has also been investigated. It was found that the
59 fluorescence intensity of CdTe QDs was quenched at 542 nm in the presence of vancomycin, and
60 the quenched intensity was proportional to the concentration of vancomycin in the large range
61 with a low detection limit. The method has been applied to determination of vancomycin in
62 environmental water samples and spiked human serum and satisfactory results were obtained. The
63 mechanisms of the proposed reaction have also been discussed.



64
65

Fig. 1 Structure of the vancomycin.


66 Results and discussion

67 GSH-CdTe QDs and the vancomycin samples were synthesized and prepared in the experimental
68 partment. The simple vancomycin measuring method based on the fluorescence of QDs was

69 constructed based on the quenching effect of vancomycin to the GSH-CdTe QDs. The detail
70 operation process of the system was performed according to the analytical applications section.

71 Morphology features characterization of GSH-CdTe QDs


72 The morphology features and diameter of the aqueous GSH-CdTe QDs were characterized by
73 the TEM and XRD (Fig. 2). As shown in TEM image of Fig. 2 (A), the as-prepared GSH-CdTe
74 QDs are uniform and mono-dispersed in shape. The diameters of the GSH-CdTe QDs have
75 average narrow sizes of about 3–4 nm. X-ray diffraction (XRD) was used to characterize the
76 crystal structure of the as-prepared CdTe Q-dots, and the XRD patterns are illustrated in Fig. 2 (B).
77 The three diffraction peaks of CdTe Q-dots at 24.60° , 38.56° , and 47.01° can be indexed to the (1
78 1 1), (2 2 0), (3 1 1) planes of cubic CdTe lattice(JCPDS card: 01-075-2086). According to the
79 method described in Ref.,²¹ the quantum yield of GSH-capped CdTe Q-dots determined by using
80 rhodamine 6G as a criterion (QY = 95 %) was about 47.5 %.



81

(A)

82



83

84

(B)

85

Fig. 2 (A) The TEM image of aqueous GSH-capped CdTe QDs. (B) XRD pattern of

86

as-prepared GSH-CdTe QDs.

87

In addition, the UV/vis absorption spectra (a) and fluorescence spectra (b) of GSH-CdTe QDs

88

were obtained as shown in Fig. 3. The UV/vis absorption spectrum revealed a strong excitonic

89

absorption in the region of ultraviolet, and the characteristic absorption peak is located at 516 nm.

90

Meanwhile, the fluorescence emission spectrum further confirmed that GSH-CdTe QDs were

91

nearly monodisperse and homogeneous because of its favorable symmetry and narrow FWHM

92

(about 42 nm), and the observed fluorescence band centered at 542 nm (excitation 350 nm). The

93


as-prepared GSH-CdTe QDs exhibited narrow fluorescence bandwidth as the consequence of

94

homogeneous size distribution and uniform crystallinity, which could be confirmed by TEM in

95

Fig. 2(A).



96

97

Fig. 3 The UV/vis absorption spectra (a) and fluorescence spectra (b) of GSH-CdTe QDs

98

(excitation 350 nm).

99

As it could be seen from Fig. 3 that the emission maximum was close to its characteristic

100

absorption peak, which indicated that the fluorescence emission of the QDs was due to the direct

101

recombination of the electrons in conduction bands and the holes in valence bands. The particle

102

size of the synthetic GSH-CdTe QDs was calculated about 3.12 nm based on the formula (1).²²

103


Obviously, the particle sizes obtained by calculation were well consistent with that got from TEM.

104

$$D = (9.8127 \times 10^{-7}) \lambda^3 - (1.7147 \times 10^{-3}) \lambda^2 + (1.0064) \lambda - 194.84 \quad (1)$$

105 **Fluorescence detection of vancomycin with GSH-CdTe QDs**


106 As control experiment, the fluorescence spectra of the GSH-CdTe QDs were recorded in the
107 absence and presence of vancomycin in Fig. 4 (A). It also can be seen from it that the as-prepared
108 GSH-CdTe QDs exhibited strong fluorescence intensity and the observed fluorescence band
109 centered at 542 nm (excitation 350 nm). After been mixed with vancomycin, the fluorescence
110 intensity of the system decreased gradually. The quenching of the fluorescence signal intensity is
111 directly related to the concentration of vancomycin added in a certain range. Based on this
112 principle, the possibility of developing a sensitive method for vancomycin has been established.



113

114

(A)



115

116

(B)

117 **Fig. 4** The fluorescence spectra of GSH-CdTe QDs-vancomycin system.

118 (A) The concentrations of vancomycin added for spectrum a – n were 0, 5, 10, 15, 20, 25, 30, 35,

119 40, 45, 50, 55 and 60 $\mu\text{g mL}^{-1}$, respectively; Inset: the intensity variation (ΔF) of the

120 fluorescence against the concentration ($0\text{--}60\ \mu\text{g mL}^{-1}$) of vancomycin.

121 (B) The concentrations of vancomycin added for spectrum a – n were 0, 2, 4, 6, 8, 10, 12, 14, 16,
122 18 and $20\ \mu\text{g mL}^{-1}$, respectively; Inset: the intensity variation (ΔF) of the fluorescence against
123 the concentration ($0\text{--}20\ \mu\text{g mL}^{-1}$) of vancomycin.

124 **Optimization of the reactions**

125 The influence of acidity on the fluorescence intensity of the aqueous GSH-CdTe
126 QDs–vancomycin solution system was investigated and the results were shown in Fig. S1. In this
127 experiment, Tris-HCl buffer solution ($0.05\ \text{mol L}^{-1}$) was used to control the acidity of analytical
128 system. The results showed that the maximum value of ΔF ($\Delta F = F_0 - F$) was obtained at pH 7.4. In
129 order to obtain a lower detection limit, so pH 7.4 was chosen to be the optimal reaction pH in this
130 experiment.

131 The influence of the GSH-CdTe QDs concentrations on the fluorescence intensity of
132 GSH-CdTe QDs–vancomycin system was investigated by means of keeping the vancomycin
133 concentrations, Tris-HCl buffer concentrations and the pH constant while changing GSH-CdTe
134 QDs concentrations. The results were shown in Fig. S2, which suggested that the GSH-CdTe QDs
135 concentration strongly affected the fluorescence intensity of the solution system and the optimal
136 concentration of GSH-CdTe QDs was $5.0 \times 10^{-5}\ \text{mol L}^{-1}$. The value of ΔF decreased when the
137 addition amount of GSH-CdTe QDs went beyond this concentration. Accordingly, the GSH-CdTe
138 QDs concentration of $5.0 \times 10^{-5}\ \text{mol L}^{-1}$ was chosen as the optimal concentration.

139 The interaction between the GSH-CdTe QDs and vancomycin was monitored at different time
140 scales at room temperature and the results were shown in Fig. S3. The results demonstrated that
141 the fluorescence spectrum intensity of the mixture presented a rapid decrease after the vancomycin
142 was added. The interaction process reached equilibrium after the reactions lasted for 10 min and
143 the equilibrium remained stable for over 100 min, indicating that certain time was need to
144 complete the interaction. Accordingly, it was not until 10 min later that we recorded the
145 fluorescence spectra to ascertain that the reactions reached equilibrium. The time scale of 10 min
146 was adopted in all of these experiments.

147 **Calibration curves and sensitivity**

148 As shown in the insert of Fig. 4 (A), within the concentration range of 0–60 $\mu\text{g mL}^{-1}$, the
149 fluorescence quenching of the GSH-CdTe QDs by vancomycin was not always in line relationship
150 with the concentration of the vancomycin, though the quenching intensity of the fluorescence
151 signal was directly proportional to the concentration of vancomycin added in a low concentration
152 range about 0–20 $\mu\text{g mL}^{-1}$. So, the relationship between the fluorescence quenching extent of the
153 GSH-CdTe QDs and the concentration of the vancomycin was investigated in a small range of
154 concentration as shown in Fig. 4 (B).

155 It clearly can be seen from the Fig. 4 (B) that, under the optimal conditions, the fluorescence
156 spectra of aqueous GSH-CdTe QDs with different concentrations of vancomycin were recorded.
157 The intensity quenching of the fluorescence signal was directly proportional to the concentration
158 of vancomycin added. As shown in the insert of Fig. 4 (B), within the range of 0–20 $\mu\text{g mL}^{-1}$, the
159 fluorescence quenching of the GSH-CdTe QDs by vancomycin fitted the following equation: ΔF
160 $= F_0 - F = 4.8636 + 118.5772 c$ (c : $\mu\text{g mL}^{-1}$), F_0 and F are the fluorescence intensity of GSH-CdTe
161 QDs in the absence and in the presence of a given vancomycin concentration, respectively. Under
162 the optimal conditions, the linear ranges of GSH-CdTe QDs fluorescence intensity versus the
163 vancomycin concentration were 1.534 ng mL^{-1} ($10\delta/k$) – 20 $\mu\text{g mL}^{-1}$ with a correlation coefficient
164 of 0.9994, and the limit of detection ($3\delta/k$) was 0.4605 ng mL^{-1} , where δ was the standard
165 deviation of eleven replicate measurements of the ratio of fluorescence intensity of the blank
166 samples, and k was the slope of the calibration. It is noteworthy that beyond the concentration
167 range, the fluorescence quenching of the system was no longer present proportional linear
168 relationship.

169 In order to verify the accuracy of the method, we diluted the vancomycin to the exact
170 concentration of 1.534 ng/mL and detected the fluorescence intensity of quantum dots system (as
171 shown in Fig. S4). As it can be seen from Fig. S4 that the fluorescence intensity of the GSH-CdTe
172 QDs changed from 5192.0 to 5187.32 after the addition of vancomycin with a concentration of
173 1.534 ng/mL , the intensity variation (ΔF) of the fluorescence was 4.68. While calculated value of
174 the fluorescence intensity got by $\Delta F = F_0 - F = 4.8636 + 118.5772 c$ (c : $\mu\text{g mL}^{-1}$) was 5.0455.
175 Compared with the calculated value got by the relational expression and the exact value got from
176 the actual measurement, we found that the accuracy of the method was up to 92.76%, which

177 indicating that the good accuracy and practicability of the method. Besides, As it can be seen from
 178 the Fig.S5 that the fluorescence intensity of the GSH-CdTe QDs quenched gradually from 5192.0
 179 to 5127.0 after the addition of vancomycin with concentration of 0, 5, 10, 50, 100, 200, 300, 400,
 180 500 ng mL⁻¹, respectively. Uniform change of the quenching value reveals the sensitivity of the
 181 GSH-CdTe QDs to vancomycin even at low concentration far less than 1 µg mL⁻¹. This
 182 contribute to the good accuracy and practicability of the method Therefore, the present method
 183 was reliable and practical in detection of vancomycin with detection limit at the level-ng ml⁻¹.

184 Compared with other different determined methods for vancomycin, as shown in Table 1, our
 185 proposed FL method displayed relatively low detection limit and wide application linear range,
 186 indicating that the FL method of using GSH-CdTe QDs as probe had its advantages compared
 187 with other methods, which might be attributed to the greatly quenched fluorescence signals of the
 188 GSH-CdTe QDs.

189 **Table 1**

Method	Matrix	Linear range (µg mL ⁻¹)	LOD ^a (µg mL ⁻¹)	Refs.
Spectrophotometry	Pharmaceutical formulation	2.0–18.0	0.020	[8]
Voltammetry	Pharmaceutical formulation	4.0–32.0	2.7	[10]
HPLC/UV	Human plasma	0.4–100.0	0.20	[11(a)]
HPLC	Rat plasma and human plasma	1.0–80.0	0.50	[11(b)]
HPLC/EC	Human plasma	0.5–50.0	0.25	[14]
LC/MS	Human serum	0.05–10.0	0.0010	[6]
LC/MS/MS	Water samples	0.016–2.0	0.010	[7]
	Rat plasma	0.01–20.0	0.0070	
HPLC/FL	Human plasma	0.005–1.0	0.0020	[11(c)]
CE/UV	Pharmaceutical formulation	0.25–5.0	0.10	[12(b)]
CL	Human serum and water samples	0.5–40.0	0.10	[20]
FL	Human serum, and water samples	0.001534–20.0	0.0004605	This work

^a Limit of detection

190 **Table 1** Analytical performance data of previously reported works for the determination of
 191 vancomycin.

192 Selectivity of the method

193 The selectivity and anti-interference ability of the FL method using GSH-CdTe QDs as probe
 194 for vancomycin detection were investigated by analyzing standard solution in existing interfering
 195 species. The influences of the foreign substances such as relevant metal ions, amino acid,

196 inorganic anions, and bio-molecules were investigated as shown in Table 2. If the coexisting
 197 substances caused a relative error of less than $\pm 5\%$ on the FL intensity change of the GSH-CdTe
 198 QDs, they were considered to have no interference with the detection of vancomycin. It was found
 199 that ions (Na^+ , K^+ , Mg^{2+} , Ca^{2+} , Zn^{2+} , Ba^{2+} , CO_3^{2-} , HCO_3^- , PO_4^{3-} , SO_4^{2-} , NO_3^- , Cl^-) and
 200 bio-molecules (Urea, common amino acids, Protamine and Albumin egg) posed no significant
 201 interference on the determination at relatively high concentration levels. Whereas, compared to
 202 other ions, Cu^{2+} has remarkable larger impact on the system, only below the concentration of
 203 $2.5 \times 10^{-6} \text{ mol L}^{-1}$, can it has no obvious influence. Besides, among the analogues of vancomycin,
 204 both Tygacil and Benzylpenicillin have little interference on the determination at relatively high
 205 concentration levels. Whereas, Ofloxacin with high concentration will has some remarkable
 206 impacts on the detection of vancomycin in the system. It has no obvious influence only below the
 207 concentration of $0.5 \mu\text{g mL}^{-1}$. Thus, when detecting vancomycin in the solutions containing a
 208 mixture of Ofloxacin, Ofloxacin should be removed or sheltered by certain Ofloxacin chelant firstly.
 209 Additionally, Adenine phosphate and Human Serum Albumin could be allowed at lower
 210 concentration levels without significant interference. Apparently, the experimental results
 211 demonstrated that the proposed method possessed high selectivity and might be applied in the
 212 detection of vancomycin in the quality control of bulk drugs and their pharmaceutical preparations
 213 with satisfactory results.

214 **Table 2**

Coexistence material	Concentration ($10^{-4} \text{ mol L}^{-1}$)	Relative error (%)	Coexistence material	Concentration ($10^{-3} \text{ mol L}^{-1}$)	Relative error (%)
$\text{Na}^+(\text{Cl}^-)$	60	+1.07	Alanine	35	+1.35
$\text{K}^+(\text{Cl}^-)$	45	-2.67	Tryptophan	50	-4.50
$\text{Mg}^{2+}(\text{Cl}^-)$	10	+1.73	L-Glutamic acid	20	+1.10
$\text{Ca}^{2+}(\text{Cl}^-)$	9	-3.37	Glycine	15	-2.50
$\text{Zn}^{2+}(\text{Cl}^-)$	15	+2.28	Isoleucine	20	-1.15
$\text{Cu}^{2+}(\text{SO}_4^{2-})$	0.025	-3.85	Sarcosine	60	-2.44
$\text{Ba}^{2+}(\text{Cl}^-)$	5	-2.25	Creatine	50	-2.45
$\text{CO}_3^{2-}(\text{Na}^+)$	20	-2.30	Adenine phosphate	10	-3.12
$\text{HCO}_3^-(\text{Na}^+)$	10	+1.45	Human serum albumin	$8 \mu\text{g mL}^{-1}$	-3.55
$\text{PO}_4^{3-}(\text{Na}^+)$	16	+3.60	Albumin egg	$35 \mu\text{g mL}^{-1}$	-2.05
$\text{SO}_4^{2-}(\text{Na}^+)$	30	+2.90	Tygacil	$5 \mu\text{g mL}^{-1}$	-3.05
$\text{NO}_3^-(\text{Na}^+)$	100	-4.00	Ofloxacin	$0.5 \mu\text{g mL}^{-1}$	-4.30
$\text{CO}(\text{NH}_2)_2$	28	-3.35	Benzylpenicillin	$5 \mu\text{g mL}^{-1}$	-1.80


215 The concentration of vancomycin was $5 \mu\text{g mL}^{-1}$.216 **Table 2** Effects of coexisting substances.

217 Mechanism investigation

218 It is known to all that fluorescence quenching mechanisms are usually be classified into two
 219 categories, either static quenching or dynamic quenching, which can be distinguished by their
 220 differing dependence on temperature.²³ The quenching rate constants increased with increasing
 221 temperature for dynamic quenching, whereas the reverse effect was observed in the case of static
 222 quenching.²⁴ To the best of our knowledge, the fluorescence quenching categories of vancomycin
 223 on GSH-CdTe QDs could be analyzed quantitatively at different temperatures with the
 224 Stern-Volmer equation.²⁵ :

$$225 \quad \frac{F_0}{F} = 1 + K_q \tau_0 [Q] = 1 + \kappa_{SV} [Q] \quad (1)$$

226 In the expression of Eq. (1), F_0 and F was the fluorescence intensity of the QDs in the absence
 227 and presence of quencher (vancomycin), respectively, K_q was the quenching constant, τ_0 was the
 228 fluorescence lifetime in the absence of quencher, κ_{SV} was the Stern-Volmer quenching constant,
 229 and $[Q]$ was the concentration of quencher.



230
 231 **Fig. 5** Stern-Volmer plots for the GSH-CdTe QDs-vancomycin system at three different
 232 temperatures (c_{QDs} : $5.0 \times 10^{-5} \text{ mol L}^{-1}$, $\text{pH} = 7.4$); the inset: the relationship between the
 233 Stern-Volmer quenching constant (κ_{SV}) and the temperature (T).

234 As shown in Fig. 5, κ_{SV} of the GSH-CdTe QDs-vancomycin system was determined according
 235 to Eq. (1) at three different temperatures (290K, 300K and 310K) by linear regression of a plot of
 236 F_0/F against $[Q]$, which was the concentration of vancomycin. The values of quenching constants
 237 (κ_{SV}) and correlation coefficient were listed in Table 3. From the Fig. 5, it clearly could be seen

238 that the Stern-Volmer quenching constant of the system increased with the rise of temperature,
 239 which indicated that the quenching type of GSH-CdTe QDs-vancomycin system was dynamic
 240 quenching.

241 **Table 3**


Temperature (K)	Stern-Volmer linear equation	κ_{SV} (mol L ⁻¹)	R ^a	R.D ^b
290	$F_0/F = 0.998 + 4.5994 \times 10^4 [Q]$	4.5994×10^4	0.9977	0.0075
300	$F_0/F = 1.001 + 5.7463 \times 10^4 [Q]$	5.7463×10^4	0.9965	0.0114
310	$F_0/F = 0.998 + 7.0389 \times 10^4 [Q]$	7.0389×10^4	0.9984	0.0095

^a R is the correlation coefficient.

^b S.D. is the standard deviation for κ_{SV} Values.

242 **Table 3** Stern-Volmer quenching constants for the GSH-CdTe QDs-vancomycin system at
 243 different temperatures (c_{QDs} : 5.0×10^{-5} mol L⁻¹, pH=7.4).

244 It was known to all that measurement of the fluorescence life time was the most persuasive way to
 245 distinguish static and dynamic quenching. To further confirm the fluorescence quenching type of
 246 GSH-CdTe QDs-vancomycin system, measurement of the fluorescence lifetime of the GSH-CdTe
 247 QDs in absence and presence of vancomycin had also been performed (as shown in Fig. 6).




248 **Fig. 6** Fluorescence decay of GSH-CdTe QDs (5.0×10^{-5} mol L⁻¹) in the absence (a) and presence
 249 (b) of vancomycin ($10 \mu\text{g mL}^{-1}$).

251 It was believed that if the static quenching takes place, the life time of the fluorescence
 252 molecule on excited state has no any change. Reversely, if dynamic quenching occurs, changes of
 253 life time must take place and it would become shorter.²⁶ It can be seen from the fluorescence
 254 emission decay curves in Fig. 6 that, after interacted with vancomycin, the life time of GSH-CdTe
 255 QDs (got by calculating method) on excited state did have changed obviously from 30.27 ns to

256 28.15 ns, which effectively demonstrated that the mechanism of the fluorescence quenching of
 257 GSH-CdTe QDs was indeed dynamic quenching rather than static quenching.

258 To explore the mechanism of quenching reaction, the electron transfer from GSH-CdTe QDs
 259 to vancomycin has also been explored. As known that upon excitation of GSH-CdTe QDs, it
 260 would lead to the promotion of electron from its valence band to conduction band, which results in
 261 the formation of a positively charged hole in its valence band and a free electron in its conduction
 262 band. The recombination of the electron and the hole of the GSH-CdTe QDs would take place and
 263 result in the fluorescence without the existence of vancomycin. Reverse, while introducing
 264 vancomycin, which serves as efficient electron acceptor for the conduction band electron from the
 265 GSH-CdTe QDs,²⁷ to the solution of QDs, it would prevent the electron-hole recombination at the
 266 interfaces of GSH-CdTe QDs (as shown in Scheme 1), which as a result caused the fluorescence
 267 quenching.²⁸




268

269

Scheme 1 Mechanism of the fluorescence quenching process.

270 In terms of dynamic quenching, it was the collision between the electron acceptor collides and
 271 the excited fluorophore that result in the occasion of charge transfer which directly lead to the
 272 fluorescence quenching. Because the collision between the quencher and the fluorophore affects
 273 only the excited state of the fluorophore, so, no changes in the absorption spectrum could be
 274 expected. On the contrary, the formation of ground-state complex in static quenching will perturb
 275 the absorption spectra of the fluorophore.²⁹ Thus, distinguishing of static and dynamic quenching
 276 could be attempted by careful examination of the absorption spectrum.



277

278

279 **Fig. 7** UV/vis absorption spectra of (a) GSH-CdTe QDs ($5.0 \times 10^{-5} \text{ mol L}^{-1}$), (b) vancomycin
280 ($40 \mu\text{g mL}^{-1}$) and (c) GSH-CdTe QDs-vancomycin system.

281 As shown in Fig. 7, the absorption spectra of GSH-CdTe QDs, vancomycin and QDs –
282 vancomycin system were separately obtained. In the spectrum of pure QDs, there is strong
283 absorption in the UV/vis at wavelengths $< 400 \text{ nm}$, whereas the absorption is relatively weak in
284 the visible. In the spectrum of pure vancomycin, there is a strong absorption peaks at 265 nm . As
285 seen, no indication of a spectral shift is observed after vancomycin was added into GSH-CdTe
286 QDs. In short, for the mixture of QDs and vancomycin, the absorption spectrum is simply a
287 superposition of the QDs and vancomycin absorption spectra. As illustrated in Fig. 7, the
288 absorption spectrum of the mixture is a linear combination of the spectra of each component,
289 indicating that the mechanism to be dynamic quenching.

290 Analytical applications

291 To evaluate the applicability of the proposed FL method to real samples, the method was
292 applied to determine the vancomycin in environmental water samples, and spiked human serum.
293 The samples were prepared according to the general procedure described in the experimental
294 section. The obtained results for environmental water samples and spiked human serum were
295 shown in Table 4. The accuracy of the method was evaluated by performing recovery experiments
296 for samples solution. The results presented in Table 4 showed that the recoveries of the
297 environmental water samples were from 96.8% to 103.4% and the relative standard deviations
298 were less than 4.33%, and the recoveries of spiked human serum were from 95.8% to 98.3% with

299 relative standard deviations of less than 4.35%, which demonstrating a good precision on this
 300 method. All of these obtained results indicated the reliability and practicality of the method.
 301 Meanwhile, the results determined by FL method are in agreement with those of pharmacopoeia
 302 method.

303 **Table 4**

Sample	Added (ng mL ⁻¹)	Found ^a (ng mL ⁻¹)	Recovery (%)
Water	0	Not detected	–
	5	4.92±0.12	98.4
Tap water	5	4.89±0.08	97.8
	10	10.25±0.13	102.5
Ground water	5	4.84±0.21	96.8
	10	9.75±0.36	97.5
River water	5	4.83±0.18	96.6
	10	10.34±0.09	103.4
Human serum sample	0	Not detected	–
	5	4.87±0.17	97.4
	10	9.83±0.36	98.3
	20	19.16±0.56	95.8

^a Mean of five determination ± standard deviation.

304 **Table 4** Results for determination of vancomycin in environmental water samples and spiked
 305 human serum samples.

306 Conclusions

307 Based on the fluorescence quenching effect of vancomycin on the GSH-CdTe QDs and the
 308 electron transfer mechanism, a Fluorescence method for determination of vancomycin with the
 309 detection limit of 0.4605 ng mL⁻¹ was reported. The preparation of GSH-CdTe quantum dots was
 310 simple and inexpensive. Under the optimal conditions, the proposed method was rapid with a
 311 linear dynamic range of 1.534 ng mL⁻¹–20 µg mL⁻¹. Moreover, it was successfully applied to the
 312 determination of vancomycin in environmental water samples, and spiked human serum with a
 313 relative standard deviations less than 4.33% and 4.35%, respectively, which characterized by
 314 simplicity, rapidity, and high sensitivity.

315 Experimental

316 Apparatus

317 The absorption spectra of QDs and vancomycin were measured on a UV-8500
 318 spectrophotometer (Tianmei Corporation, Shanghai, China). All fluorescence spectra were
 319 recorded on a Hitachi F-2500 spectrofluorophotometer (Hitachi, Japan). JEOL JEM-2100 high

320 resolution transmission electron microscopy (TEM, Hitachi, Japan) was adopted to examine the
321 appearance and size of nanoparticles. XD-3 X-ray diffraction (XRD, Purkinje General Instrument
322 Co., Ltd., Beijing, China) were adopted to examine the appearance and size of nanoparticles. A
323 FL-TCSPC Fluorolog-3 fluorescence spectrometer (Horiba Jobin Yvon Inc., Paris, France) was
324 used to measure the fluorescence lifetime of the GSH-CdTe QDs in the absence/presence of
325 vancomycin at room temperature. A PHS-3C pH meter (Leici, Shanghai, China) was used to
326 measure the pH values of the aqueous solutions.

327 **Chemicals**

328 Cadmium chloride hemi (pentahydrate) ($\text{CdCl}_2 \cdot 2.5\text{H}_2\text{O}$) and Te powder were purchased from
329 Aladdin Reagent Co. (Shanghai, China). Sodium borohydride (NaBH_4) was obtained from
330 Sinopharm Chemical Reagent Co. (Shanghai, China). Glutathione (GSH) and all other chemicals
331 and reagents used in this work were obtained from Aladdin Reagent Co. (Shanghai, China).
332 Tris-HCl buffer solutions with different pH values were prepared according to suitable proportions.
333 All reagents used were of at least analytical grade and used without further purification. Drug-free
334 human serum used in this study was taken from healthy volunteers and stored in freezer until
335 analysis. Ultrapure water ($18.2 \text{ M}\Omega \text{ cm}$) was used throughout the experiment.

336 **Synthesis of GSH capped CdTe QDs**

337 GSH modified aqueous CdTe QDs were synthesized according to the previously reported
338 method with a slight modification.¹⁸ Firstly, Te powder (0.0383 g) and water (10 mL) were placed
339 in a 50 mL three-necked flask. Excess amount of NaBH_4 was added under magnetic stirring.
340 Subsequently, the colorless solution of NaHTe was obtained. Then $\text{CdCl}_2 \cdot 2.5\text{H}_2\text{O}$ (0.1028 g) and
341 GSH (0.1847 g) were dissolved in 150 mL ultrapure water, and the pH was adjusted to 11.20 by
342 addition of 1 mol L^{-1} NaOH solution dropwise. In addition, H_2SO_4 (0.5 mol L^{-1}) was introduced
343 dropwise to NaHTe solution to produce H_2Te gas, which passed through the cadmium precursor
344 with a slow Ar flow for 35 min. At this stage, CdTe precursors were formed. The resulting
345 mixture was subjected to reflux for 90 min under open-air condition with a condenser. The
346 GSH-CdTe QDs with a concentration of $2.0 \times 10^{-3} \text{ mol L}^{-1}$ were obtained. The concentration of
347 GSH capped CdTe QDs was dependent on the HTe^- concentration.¹⁹

348 **Pretreatment of real samples solution**

349 A 100 $\mu\text{g mL}^{-1}$ stock standard solution of vancomycin was prepared by dissolving 25 mg
350 vancomycin in 500 mL ultrapure water and stored at 4 $^{\circ}\text{C}$ in refrigerator. Tap water was analyzed
351 without any retreatment. Ground and river water samples were freshly collected and filtered with
352 polyamide embrane filters of 0.45 μm to eliminate the suspended solid matter and stored in dark at
353 4 $^{\circ}\text{C}$ in the refrigerator.²⁰ They were used within 1 week. Prior to analysis, the water samples
354 were spiked with the standard vancomycin solutions (100 $\mu\text{g mL}^{-1}$) and diluted to different
355 concentrations, respectively. For human serum samples, an extraction process was not needed
356 except a deproteinization pretreatment step utilizing trichloroacetic acid was performed. To
357 prepare the spiked samples, certain amounts of vancomycin were spiked into 2.0 mL of
358 protein-free serum and then diluted to different concentrations with ultrapure water.

359 Analytical procedure

360 In order to determine the interaction between GSH-CdTe QDs and vancomycin, a series of
361 different concentrations of vancomycin samples and an appropriate amount of Tris-HCl solution
362 were mixed into a 10 mL volumetric flask. Then certain amount of above GSH-CdTe QDs was
363 added and the mixture was diluted to the calibration mark on the neck of the flask with ultrapure
364 water and shaken thoroughly to be mixed completely. The typical reaction mechanism was shown
365 in Scheme 1. After incubation for 10 min, the fluorescence intensity of the resulting solution was
366 measured at the excitation wavelength of 350 nm. The resulting solutions were investigated by
367 fluorescence, UV/vis absorption spectroscopy and fluorescence lifetime.

368 Acknowledgements

369 This work was supported by Chongqing Municipal Key Laboratory on Luminescence and
370 Real-Time Analysis, Southwest University (CSTC, 2006CA8006) and the National Natural
371 Science Foundation of China (No. 21175015).

372 References

- 373 1 (a) E.M. Ali, Y.G. Zheng, H.H. Yu, J.Y. Ying, *Anal. Chem.*, 2007, **79**, 9452.; (b) S.L. Hu, Q.
374 Zhao, Q. Chang, J.L. Yang, J. Liu, *RSC Adv.*, 2014, DOI: 10.1039/C4RA06371F; (c) K.K.W.
375 Lo, S. P.Y Li and K. Y. Zhang, *New J. Chem.*, 2011, **35**, 265.
- 376 2 (a) W. Chidawanyika, C. Litwinski, E. Antunes, T. Nyokong, *J. Photochem. Photobio. A:*

- 377 *Chem.*, 2010, **212**, 27; (b) B.Q. Sun, W.Z. Xie, G.S. Yi, D.P. Chen, Y.X. Zhou, J. Cheng, *J.*
378 *Immunologi. Methods*, 2001, **249**, 85.
- 379 3 (a) F.L. Gao, J.P. Lei, H.X. Ju, *RSC Adv.*, 2013, **3**, 13163; (b) X. Wang, X.H. Lou, Y. Wang,
380 Q.C. Guo, Z. Fang, X.H. Zhong, H.J. Mao, Q.H. Jin, L. Wu, H. Zhao, J.L. Zhao, *Biosen. and*
381 *Bioelect.*, 2010, **25**, 1934; (c) W.J. Liang, Z.Q. Liu, S.P. Liu, J.D. Yang, Y.Q. He, *Sen. and*
382 *Actu. B*, 2014, **196**, 336.
- 383 4 (a) K.C. Nicolaou, C.N.C. Boddy, S. Br äse, N. Winssinger, *Angew. Chem. Int. Edi.*, 1999,
384 **38**, 2096; (b) M.D. Nailor, J.D. Sobel, *Med. Clin. N. A.*, 2011, **95**, 723.
- 385 5 T.S. Li, R.Y. Sheng, C. J. Ne. *Drugs*, 2001, **10**, 615.
- 386 6 T. Zhang, D.G. Watson, C. Azike, J.N.A. Tettey, A.T. Stearns, A.R. Binning, C.J. Payne, *J.*
387 *Chromat. B*, 2007, **857**, 352.
- 388 7 B. Li, T. Zhang, Z. Xu, H.H.P. Fang, *Anal. Chim. Acta.*, 2009, **645**, 64.
- 389 8 (a) S.M. El-Ashry, F. Belal, M.M. El-Kerdawy, D.R.E. Wasseef, *Microchim. Acta*, 2000,
390 **135**, 191; (b) C.S.P. Sastry, T.S. Rao, P.S.N.H.R. Rao, U.V. Prasad, *Microchim. Acta*, 2002,
391 **140**, 109; (c) M.M.D.C. Vila, A.A. Salom ão, M. Tubino, *Ecl á. Qu ín.*, 2008, **33**, 67; (d)
392 A.M. El-Didamony, A.S. Amin, A.K. Ghoneim, A.M. Telebany, *Cen. Eur. J. Chem.*, 2006,
393 **4**, 708.
- 394 9 (a) M.T. Lam, X.C. Le, *Analyst*, 2002, **127**, 1633; (b) S.Y. Tetin, K.M. Swift, E.D. *Anal.*
395 *Biochem.*, 2002, **307**, 84.
- 396 10 F. Belal, S.M. El-Ashry, M.M. El-Kerdawy, D.R. El-Wasseef, *Arzneimittel-Forsch./Dru.*
397 *Res.*, 2001, **51**, 763.
- 398 11 (a) K.J.V. Lopez, D.F. Bertoluci, K.M. Vicente, A.M. Dell'Aquila, S.R.C.J. Santos, *J.*
399 *Chromatograph. B*, 2007, **860**, 241; (b) M. Hagihara, C. Sutherland, D.P. Nicolau, *J.*
400 *Chromatograph. Sci.*, 2013, **51**, 201; (c) K. Abu-Shandi, *Anal. Bioanal. Chem.*, 2009, **395**,
401 527; (d) A. Tariq, M.R. Siddiqui, J. Kumar, D. Reddy, P.S. Negi, M. Chaudhary, S.M.
402 Srivastava, R. Singh, *Sci. Asia*, 2010, **36**, 297.
- 403 12 (a) P.J. Bonnici, M. Damen, J.C.M. Waterval, A.J.R. Heck, *Anal. Biochem.*, 2001, **290**, 292;
404 (b) A. Musenga, R. Mandrioli, V. Zecchi, B. Luppi, S. Fanali, M.A. Raggi, *J. Pharmaceuti.*
405 *Biomed. Anal.*, 2006, **42**, 32; (c) D.L. LeTourneau, N.E. Allen, *Anal. Biochem.*, 1997,

- 406 **246**, 62.
- 407 13 (a) N. Shibata, M. Ishida, Y. Venkata Rama Prasad, W. Gao, Y. Yoshikawa, K. Takada, *J*
408 *Chromatograph. B*, 2003, **789**, 211; (b) C. Cheng, S. Liu, D. Xiao, J. Hollembaek, L.
409 Yao, J. Lin, S. Hansel, *J Chromatograph. B*, 2010, **878**, 2831; (c) M. Seifrtov \acute{a} L.
410 Nov \acute{a} kov \acute{a} C. Lino, A. Pena, P. Solich, *Anal. Chim. Acta*, 2009, **649**, 158.
- 411 14 P. Favetta, J. Guitton, N. Bleyzac, C. Dufresne, J. Bureau, *J. Chromatograph. B:*
412 *Biomed. Sci. Appli.*, 2001, **751**, 377.
- 413 15 M.M.D.C. Vila, R.M.d. Oliveira, M.M. Goncalves, M. Tubino, *Qu \acute{m} ica Nova.*, 2007, **30**,
414 395.
- 415 16 Anu Saini, Jasminder Singh, Rajinder Kaur, Narinder Singh and Navneet Kaur *New J.*
416 *Chem.*, 2014, **38**, 4580.
- 417 17 M. Koneswaran, R. Narayanaswamy, M. Koneswaran, R. Narayanaswamy, *Sens. Actu. B*,
418 2009, **139**, 104.
- 419 18 Y.F. Liu and J.S. Yu, *J.col. inter. Sci.*, 2009, **333**, 690.
- 420 19 Y.L. Wu, F. He, X.W. He, X.Y. Li, Y.K. Zhang, Spectroscopic studies on the interaction
421 between CdTe nanoparticles and lysozyme, *Spectrochim. Acta A*, 2008, **71**, 1199.
- 422 20 A.R. Khataee, A. Hasanzadeh, M. Iranifam, M. Fathinia, Y. Hanifehpour, S.W. Joo,
423 *Spectrochim. Acta A*, 2014, **122**, 737.
- 424 21 G.A. Crosby, J.N. Demas, *J. Phys. Chem.*, 1971, **75**, 991.
- 425 22 W.W. Yu, L.H. Qu, W.Z. Guo, X.G. Peng, *Chem. Materials.*, 2003, **15**, 2854.
- 426 23 J.R. Lakowica, *Principles of Fluorescence Spectroscopy, 2nd ed.*, Plenum Press, New York,
427 1999, 237.
- 428 24 G.Z. Chen, X.Z. Huang, J.G. Xu, Z.Z. Zheng, Z.B. Wang, *Meth. Fluo. Anal. 2nd ed.*, Beijing
429 *Science Press*, 1990, pp. 2.
- 430 25 R. Lakowicz, *Principles of Fluorescence Spectroscopy, 3rd ed.*, Spri. Sci. Busi. Media, New
431 York, 2006.
- 432 26 X.J. Gan, S.P. Liu, Z.F. Liu, X.L. Hu, *J. Fluores.*, 2012, **22**, 129.
- 433 27 (a) A. Kathiravan, R. Renganathan, *Spectrochim. Acta A*, 2008, **71**, 1106; (b) A. Kathiravan,
434 V. Anbazhagan, M. Asha Jhonsi, R. Renganathan, *Spectrochim. Acta A*, 2008, **70**, 615.

- 435 28 S. Jagadeeswari, M. Asha Jhonsi, A. Kathiravan, R. Renganathan, *J. Lumin.*, 2011, **131**,
436 597.
- 437 29 C.D. Geddes, *Measur. Sci. Technol.*, 2001, **12**, R53.